Início › Câncer de Pulmão de Não Pequenas Células › Califórnia › Mountain View
Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em Mountain View, CA
21 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em Mountain View e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RecrutandoFase 1/2
- Stanford Cancer Institute (Melanoma/NSCLC), Stanford · a 5 mi de distância
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecrutandoFase 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · a 5 mi de distância
- Stanford Cancer Institute Palo Alto, Palo Alto · a 5 mi de distância
Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
RecrutandoFase 3
- Stanford University, Stanford · a 5 mi de distância
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
RecrutandoFase 2
- Stanford Cancer Institute, Stanford · a 5 mi de distância
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecrutandoEstudo observacional
- Stanford University, Palo Alto · a 5 mi de distância
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
RecrutandoFase 2
- Stanford Cancer Institute, Stanford · a 5 mi de distância
- Stanford Hospital and Clinics, Stanford · a 5 mi de distância
- Stanford Hospital Investigational Drug Services, Stanford · a 5 mi de distância
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RecrutandoFase 3
- Stanford Cancer Center, Palo Alto · a 5 mi de distância
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecrutandoFase 1/2
- Stanford Cancer Institute, Stanford · a 5 mi de distância
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
RecrutandoFase 1/2
- Stanford University Medical Center - Neurology, Stanford · a 5 mi de distância
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RecrutandoFase 3
- Palo Alto Medical Foundation Research Center, Palo Alto · a 5 mi de distância
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
RecrutandoFase 1/2
- Stanford Cancer Institute, Stanford · a 5 mi de distância
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
RecrutandoFase 1/2
- Stanford University Medical Center, Stanford · a 5 mi de distância
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RecrutandoFase 1
- Stanford University Medical Center, Palo Alto · a 5 mi de distância
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RecrutandoFase 1
- Stanford University, Palo Alto · a 5 mi de distância
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RecrutandoFase 1/2
- Stanford University - Stanford Cancer Institute, Stanford · a 5 mi de distância
A Study of LY4175408 in Participants With Advanced Cancer
RecrutandoFase 1
- Stanford Medicine Cancer Center, Stanford · a 5 mi de distância
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RecrutandoFase 1/2
- Stanford University, Stanford · a 5 mi de distância
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
RecrutandoFase 1/2
- Stanford Women's Cancer Center, Palo Alto · a 5 mi de distância
Engagement of Veterans With Lung Cancer
Recrutando
- Veterans Affairs Palo Alto Health Care System (VAPAHCS), Palo Alto · a 5 mi de distância
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Stanford · a 5 mi de distância
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RecrutandoFase 1
- Stanford University, Stanford · a 5 mi de distância
Ensaios de Câncer de Pulmão de Não Pequenas Células em outras cidades
- Houston, TX145 estudos
- New York City, NY121 estudos
- Arlington, VA104 estudos
- Nashville, TN97 estudos
- Boston, MA90 estudos
- Los Angeles, CA87 estudos
- St. Louis, MO73 estudos
- Chicago, IL61 estudos
- Baltimore, MD60 estudos
- San Antonio, TX59 estudos
- Columbus, OH57 estudos
- Washington, DC55 estudos
Outros estudos em Mountain View
- Câncer (todos os tipos)40 estudos
- Câncer de Mama26 estudos
- Câncer Metastático25 estudos
- Leucemia Mieloide Aguda19 estudos
- Câncer de Ovário19 estudos
- Transtorno do Espectro Autista17 estudos
- Câncer de Pulmão17 estudos
- Câncer de Próstata15 estudos
- Insuficiência Cardíaca15 estudos
- Autismo13 estudos
- Leucemia Linfoblástica Aguda13 estudos
- Câncer Colorretal13 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.